Article info
PDFCorrespondence response
Response to: ‘Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’’ by Perricone et al
- Correspondence to Dr Michael H Pillinger, Rheumatology, New York University School of Medicine, New York, NY 10003, USA; Michael.Pillinger{at}nyulangone.org
Citation
Response to: ‘Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’’ by Perricone et al
Publication history
- Received January 20, 2021
- Accepted January 21, 2021
- First published January 28, 2021.
Online issue publication
March 10, 2023
Article Versions
- Previous version (28 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage